Key Insights

Highlights

Success Rate

84% trial completion

Published Results

16 trials with published results (13%)

Research Maturity

51 completed trials (42% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

8.3%

10 terminated out of 121 trials

Success Rate

83.6%

-2.9% vs benchmark

Late-Stage Pipeline

7%

9 trials in Phase 3/4

Results Transparency

31%

16 of 51 completed with results

Key Signals

16 with results84% success

Data Visualizations

Phase Distribution

92Total
Not Applicable (27)
Early P 1 (1)
P 1 (20)
P 2 (35)
P 3 (7)
P 4 (2)

Trial Status

Completed51
Recruiting24
Unknown23
Terminated10
Withdrawn7
Active Not Recruiting4

Trial Success Rate

83.6%

Benchmark: 86.5%

Based on 51 completed trials

Clinical Trials (121)

Showing 20 of 20 trials
NCT03030404Completed

Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer

NCT06263088Not ApplicableRecruiting

EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.

NCT07578571Phase 1Recruiting

A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

NCT06673329Phase 1Recruiting

Brodalumab in the Treatment of Immune-Related Adverse Events

NCT05187182Phase 1Recruiting

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

NCT07540169Not ApplicableRecruitingPrimary

The Effect of Stress Ball on Nausea, Anxiety, and Fatigue in Patients With Stomach Cancer

NCT07504367Not ApplicableRecruiting

Large Language Models Assist in Tumor MDT

NCT06447064Recruiting

Cancer Loyalty Card Study 2 (CLOCS-2)

NCT07070466Phase 2Recruiting

Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA

NCT04426669Phase 1Completed

A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering

NCT04907643Not ApplicableRecruiting

Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

NCT05489250Terminated

The PLATON Network

NCT07387237Completed

Multigene Germline Panel Testing in Gastric Cancer Patients in Portugal

NCT06821048Phase 1Recruiting

Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors

NCT07354711Phase 1Recruiting

A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors

NCT05366881Recruiting

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

NCT07323186Not ApplicableNot Yet RecruitingPrimary

Evaluation of the NEOmom® Gastric Video Capsule for Gastric Cancer Screening

NCT06715839Not ApplicableRecruiting

Target-specific immunoPET Imaging of Digestive System Carcinoma

NCT07310888Not ApplicableRecruitingPrimary

Robotic Gastrectomy With 5th Arm

NCT01048281RecruitingPrimary

Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

Scroll to load more

Research Network

Activity Timeline